OmniAb, Inc. (OABI) Stock Score, Valuation & Financial Research
OmniAb, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 24/100.
Quick answer for OABI
OmniAb, Inc. currently has a Wall Street Score of 24/100. The stored market price is $4.07. Its financial score is 12/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What OmniAb, Inc. does
OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structura
OABI financial snapshot
- Wall Street Score:
- 24/100
- Current price:
- $4.07
- Market capitalization:
- $590.0M
- Revenue:
- $28.9M
- Net income:
- $-54.3M
- Free cash flow:
- $-37.0M
- Cash:
- $29.0M
- Total debt:
- $19.7M
- EPS:
- -0.57
- Financial score:
- 12/100
- Valuation score:
- 0/100
- Revenue score:
- 21/100
What stands out
- Reported year-over-year revenue growth is +0.5%.
- Free cash flow is $-37.0M, showing cash burn in the current stored period.
- The balance sheet shows $29.0M of cash versus $19.7M of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 12/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research OABI
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.